Published in final edited form as:

Bioorg Med Chem Lett. 2017 June 01; 27(11): 2296–2301. doi:10.1016/j.bmcl.2017.04.043.

Optimization of M₄ positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate *in vivo* tool compound for translational pharmacology

Bruce J. Melancon^{a,b}, Michael R. Wood^{a,c}, Meredith J. Noetzel^{a,b}, Kellie D. Nance^a, Eileen M. Engelberg^a, Changho Han^a, Atin Lamsal^a, Sichen Chang^a, Hyekyung P. Cho^{a,b}, Frank W. Byers^a, Michael Bubser^a, Carrie K. Jones^{a,b,e}, Colleen M. Niswender^{a,b,e}, Michael W. Wood^d, Darren W. Engers^{a,b}, Dedong Wu^f, Nicholas J. Brandon^d, Mark E. Duggan^d, P. Jeffrey Conn^{a,b,e}, Thomas M. Bridges^{a,b,*}, and Craig W. Lindsley^{a,b,c,*}

^aVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA

^bDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

^cDepartment of Chemistry, Vanderbilt University, Nashville, TN 37232, USA

^dAstraZeneca, Neuroscience, Innovative Medicines & Early Development, Waltham, Massachusetts 02451 USA

^eVanderbilt Kennedy Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

^fAstraZeneca, Pharmaceutical Science, 35 Gatehouse Drive, Waltham, MA 02451, USA

Abstract

This letter describes the further chemical optimization of the 5-amino-thieno[2,3-*c*]pyridazine series (VU0467154/VU0467485) of M₄ positive allosteric modulators (PAMs), developed via iterative parallel synthesis, culminating in the discovery of the non-human primate (NHP) *in vivo* tool compound, VU0476406 (**8p**). VU0476406 is an important *in vivo* tool compound to enable translation of pharmacodynamics from rodent to NHP, and while data related to a Parkinson's disease model has been reported with **8p**, this is the first disclosure of the optimization and discovery of VU0476406, as well as detailed pharmacology and DMPK properties.

Graphical abstract

To create your abstract, type over the instructions in the template box below. Fonts or abstract dimensions should not be changed or altered.9.0_/0

*To whom correspondence should be addressed: thomas.m.bridges@vanderbilt.edu and craig.lindsley@vanderbilt.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

M_4 ; Muscarinic acetylcholine receptor; Positive allosteric modulator (PAM); Non-human primate (NHP); Structure-Activity Relationship (SAR)

Muscarinic acetylcholine receptor subtype 4 (M_4) positive allosteric modulators (PAMs) represent a fundamentally new approach to treat multiple symptom domains of schizophrenia, Huntington's disease and Parkinson's disease (PD).^{1–12} M_4 PAMs (Figure 1) represent the extreme of allosteric modulator caveats in terms of steep SAR, species differences in pharmacology (rat versus human versus cynomolgus (cyno) monkey versus dog M_4 PAM potency, affinity/cooperativity and subtype selectivity), poor solubility, and/or low CNS penetration.^{3,10–16} Work in this area has been challenging since the first report by Eli Lilly of **1**, a human-preferring M_4 PAM.¹ Subsequent optimization efforts afforded **2**, which provided the first *in vivo* proof-of-concept (POC) for selective M_4 potentiation of endogenous acetylcholine in reversing amphetamine-induced hyperlocomotion (AHL) in rats.³ Further efforts improved physiochemical/DMPK properties and delivered the *in vivo* rodent POC tool compound, **3**.^{11,15} Finally, **4** afforded a balance in M_4 PAM activity across species, and was evaluated in depth as our first potential M_4 PAM clinical candidate.¹⁶ Despite these advances, we required an *in vivo* non-human primate (NHP) POC tool compound for use in translational efficacy studies, primate PD models and biomarker studies that could be freely shared with collaborators. In this Letter, we detail the discovery effort that led to VU0467406, an *in vivo* M_4 PAM non-human primate (NHP) tool compound.

As **4** offered balanced M_4 PAM activity across species, we focused our efforts on this chemotype.¹⁶ A multitude of substituted benzyl amides had previously been explored, and SAR suggested a large lipophilic binding pocket accessible to the 4-position substituent, e.g., the 4-SO₂CF₃ moiety of **3** and related analogs. Interestingly, and despite their prevalence in GPCR ligands, we never synthesized and evaluated any biaryl or heterobiaryl methyl amide congeners; therefore, we focused our search for an NHP *in vivo* tool within this unexplored chemical space.

The synthesis of analogs **8** proved to be straightforward. Condensation of commercially available 3-chloro-5,6-dimethylpyridazine-4-carbonitrile **5** with methyl thioglycolate under basic conditions smoothly affords the sodium carboxylate **6** in 78% yield. A HATU-mediated amide coupling with 2-, 3- or 4-bromobenzyl amines then delivers analogs **7** in yields ranging from 45–92%. A subsequent Stille or Suzuki cross-coupling reaction with a diverse range of aryl and heteroaryl moieties delivers analogs **8** in yields ranging from 58–90%.¹⁷

SAR was driven using activity at the human M_4 receptor (potency in functional assay), but key compounds were assessed on rat and cyno M_4 as well, as the goal was an NHP tool

compound. As shown in Table 1, many potent human M₄ PAMs were discovered and several displayed attractive DMPK profiles and excellent CNS penetration (brain:plasma K_p and K_{p,uu}) *vide infra*. Initial evaluation of the 2-, 3- and 4-bromobenzyl derivatives, **7a–c** respectively, demonstrated a clear preference for 3- and 4- substitution. Conversion of these into the corresponding biaryl analogs, **8a–c**, confirmed the finding, with the 2-phenyl derivative **8a** inactive (hM₄ EC₅₀ >10 μM), the 3-phenyl congener **8b** weak (hM₄ EC₅₀ = 1.65 μM) while the 4-phenyl derivative **8c** displayed good M₄ PAM activity (hM₄ EC₅₀ = 319 nM). Thus, future efforts focused solely on 4-substituted biaryl and heterobiaryl analogs **8d–p**. PAM **8c** showed low efficacy and poor physiochemical properties and a high cLogP (>4); therefore, we elected to evaluate diverse azaheterocycles in an attempt to improve physiochemical properties, enable salt formation and lower lipophilicity. Exploration of the pyridyl biaryl analogs **8d–f** showed robust SAR. Potency increased as the pyridine nitrogen was moved from the 2-position (**8d**, hM₄ EC₅₀ = 232 nM), to the 3-position (**8e**, hM₄ EC₅₀ = 103 nM) and finally to the 4-position (**8f**, hM₄ EC₅₀ = 36 nM). Other heterocycles such as pyridazine (**8g**), pyrazine (**8h**), pyrimidine (**8i** and **8j**) were also well tolerated. Attempts to modulate the pyridine basicity in **8d–f** by the incorporation of fluorine atoms, as in **8k–p**, afforded a broad spectrum of activity, with **8k**, **8m** and **8p** displaying good hM₄ PAM potency and efficacy. From these initial analogs, PAMs **8f**, **8k**, **8m** and **8p** were selected for more in-depth DMPK profiling.

As shown in Table 2, all four PAMs showed attractive cLogPs (2.66 to 2.92) and conserved TPSAs with molecular weights below 500. All were highly bound in plasma, except **8f**, which also showed low rat clearance *in vivo* (despite high *in vitro* predicted rat CL_{hep}, a likely consequence of excluding fu_{plasma}/fu_{mic} terms from the well-stirred equation used for prediction) and high rat CNS penetration (brain:plasma K_p = 0.94, K_{p,uu} = 1.1). However, **8f**, as expected due to the naked pyridine ring, was a potent inhibitor of multiple CYP₄₅₀s (IC₅₀s < 10 μM), including 3A4 (IC₅₀ = 340 nM). Similarly, both **8k** and **8m** were potent inhibitors of 1A2 (IC₅₀s of 2.5 μM and 790 nM, respectively) with low rat *in vivo* clearance (CL_{ps} of 3.6 and 1.7 mL/min/kg, respectively) and moderate total brain distribution (K_{ps} <0.21). Here, **8p** stood out, with an improved CYP inhibition profile (all IC₅₀s > 11 μM) and favorable rat PK (CL_p = 1.6 mL/min/kg, elim. t_{1/2} = 2.7 hr) despite a moderate K_p (0.11), an attractive K_{p,uu} (1.2). Moreover, **8p** was not a human P-gp substrate *in vitro* (ER = 1.7). However, we noted a lack of an *in vitro/in vivo* correlation (IVIVC) between the *in vitro* predicted CL_{hep} and the *in vivo* CL_p. Employing a revised prediction method (inclusion of binding terms in the well-stirred model), the predicted rat CL_{hep} decreased to 0.49 mL/min/kg, and a more robust IVIVC resulted.

While **8p** emerged as the most attractive of the analogs of **8** that were surveyed, we wanted to explore modifications to the benzylic phenyl ring before initiating a more exhaustive profiling effort around **8p**. While many analogs in which fluorine atoms and/or nitrogen atoms were added retained excellent M₄ PAM potency (EC₅₀s < 200 nM), all suffered from increased cLogP, poor *in vitro/in vivo* clearance and/or unacceptable CYP inhibition profiles. Thus, **8p** was advanced as a potential NHP tool compound.

Next, **8p** was evaluated as an M₄ PAM across multiple species (Figure 2). Unlike all predecessors (except **4**), **8p** was a potent M₄ PAM at the rat (rM₄ EC₅₀ = 13.5 nM, pEC₅₀ = 7.93±0.17, 72±4% ACh Max), human (hM₄ EC₅₀ = 91.0 nM, pEC₅₀ = 7.04±0.11, 74±3% ACh Max), dog (dM₄ EC₅₀ = 111 nM, pEC₅₀ = 6.95±0.12, 49±4% ACh Max) and cyno receptors (cM₄ EC₅₀ = 87.3 nM, pEC₅₀ = 7.06±0.25, 64±2% ACh Max). ACh concentration response curve (CRC) fold-shift Ca²⁺ mobilization and ACh competition binding (with [³H]-N-methylscopolamine) assays provided operational model parameters for **8p** at rM₄ (K_B = 0.37 μM, α = 8.4, β = 9.1), hM₄ (K_B = 2.8 μM, α = 7.0, β = 21), and cyno M₄ (K_B = 2.1 μM, α = 28.2, β = 2.5); all experiments are n=3–4, performed in duplicate. Moreover, **8p** was inactive (EC₅₀ > 30 μM) at both rat and human M1-3,5 (and also inactive at dog and cyno M₂, data not shown). These data were highly noteworthy and indicated that **8p** was a potent and highly-selective NHP M₄ PAM. A broad secondary pharmacology panel (Cerep) revealed only one sub-micromolar off-target activity for **8p** – a rat GABA_A receptor (benzodiazepine site) binding IC₅₀ = 0.44 μM, which was subsequently de-risked by a functional assay determination (no activity at 10 μM). A functional electrophysiology hERG assay with **8p** was likewise clean (IC₅₀ > 33 μM), and a mini-Ames assay (TA98 and TA100 strains ± S9) was negative for mutagenicity. In addition, **8p** was devoid of evidence for CYP 1A2/2B6/3A4 induction potential in cryopreserved human hepatocytes (48 hr incubation with enzyme activity readout; EC₅₀s > 50 μM, E_{max}s < 2), and in a 4 day sub-chronic dosing rat study (10 mg/kg, QD PO, *n* = 2), the day 4 versus day 1 AUC_{0-∞} ratio was 0.77, indicating little to no auto-induction *in vivo* in rat.

Compound **8p** was found to possess a largely attractive PK profile across species. In rat, **8p** as a 10 mg/kg solution dose achieved good oral bioavailability (61% F), and the HCl salt of **8p**, when dosed as a suspension, achieved 54 %F. PAM **8p** likewise exhibited favorable IV and PO PK in dog (CL_p = 5.5 mL/min/kg, elim. t_{1/2} = 1.0 hour, V_{ss} = 0.70 L/kg, and 47 %F from 3 mg/kg suspension dose of the HCl salt) and favorable IV PK in cynomolgus monkey (CL_p = 9.3 mL/min/kg, elim. t_{1/2} = 1.3 hours, V_{ss} = 0.87 L/kg), but with low oral bioavailability (4.7 %F from 10 mg/kg solution dose of HCl salt). CNS penetration of **8p** was also assessed in dog (brain:plasma K_p = 0.74, K_{p,uu} = 2.6, C_{csf}:C_{plasma,u} = 4.8 at 2.0 hr; via a terminal study) and NHP (brain:plasma K_p = 0.75, K_{p,uu} = 1.1, C_{csf}:C_{plasma,u} = 1.0 at 1 hr; via a PET study measuring brain distribution of [¹⁸F]-VU0476406 after IV administration),¹⁸ providing strong support for the utility of **8p** in NHP behavioral models and biomarker studies.

Encouraged, we performed additional studies to evaluate **8p** (VU0476406) as a potential candidate for clinical development before releasing it as a public M₄ PAM NHP tool compound. *In vitro* metabolite identification experiments employing cryopreserved hepatocytes found low turnover and no evidence for human unique metabolites, with rat and cyno anticipated to provide adequate coverage of human metabolites (Figure 3). Human CYP₄₅₀ phenotyping experiments revealed that multiple CYPs (3A4 (predominant), 2D6, 2C19, 2C9 and 1A2) contribute to **8p**'s metabolism. Moreover, no significant levels of GSH conjugates were observed in reactive metabolism/bioactivation experiments with human hepatic microsomes, which further bolstered the potential to advance **8p**.

Human PK prediction, utilizing multiple approaches, suggested that **8p** would exhibit low clearance in man (CL_p between 1.3 to 3.6 mL/min/kg) with a 6–17 hour half-life.¹⁹ However, for projected 12-hour daily coverage (targeting an efficacious C_{min} scaled from rat *in vivo* pharmacodynamic studies; data not shown), **8p** was projected to require moderate to high BID oral doses (370–850 mg) due in large part to moderate predicted human oral F. In parallel, pharmaceutical science work on both the free base and HCl salt was performed, which found **8p** to be highly crystalline with low aqueous solubility ($< 0.5 \mu\text{M}$ for free base at pH 7.4) and without a clean melt (free base decomposes at 243–246 °C), suggesting potential challenges to achieving requisite margins in nonclinical safety and toxicology studies. An X-ray crystal structure proved telling (Figure 4), highlighting a network of intra- and inter-molecular hydrogen bonds forming a tight, helix-like packing with highly ordered π -stacking. Efforts to disrupt this network to enable acceptable solubility/dissolution with vehicles suitable for IND-enabling safety and toxicology studies were not successful. Thus, based on the suboptimal physiochemical properties of **8p** and the high projected human doses, the program team decided to release **8p** as a publicly available NHP M₄ PAM tool compound.

Upon release, Surmeier and co-workers evaluated **8p** (VU0476406) in both mouse and NHP models of L-DOPA-induced dyskinesia (LID), and found that administration of the M₄ PAM ameliorates deficits in synaptic plasticity and behavior in PD-LID mice and NHPs.²⁰ Specifically, **8p** dosed at 10 mg/kg IV (route chosen due to low cyno oral F, *vide supra*) significantly reduced dyskinesia scores and involuntary movements in NHPs, thus providing early proof-of-concept for M₄ PAMs in the management of Parkinson's disease and highlighting the utility of the compound **8p** (VU0476406) in NHP studies.

In summary, we have detailed the discovery and characterization of the first reported M₄ PAM non-human primate *in vivo* tool compound **8p** (VU0476406), with similar M₄ PAM activity across species. The studies presented here produced a required *in vivo* NHP POC tool compound for use in translational efficacy studies, primate PD models and biomarker studies that could be freely shared with collaborators. Initial results demonstrated that **8p** significantly reduces dyskinesia scores and involuntary movements in NHPs, and provided early POC for M₄ PAMs in the management of PD-LID. Further optimization efforts en route to M₄ PAM clinical candidates for the treatment of schizophrenia and other disorders will be reported in due course.

X-ray crystallographic data

The X-ray crystal structure data for **8p** was submitted to the Cambridge Crystallographic Data Centre (<http://www.ccdc.cam.ac.uk>) and assigned CCDC 1538487.

Acknowledgments

We thank the NIH for funding via the NIH Roadmap Initiative 1X01 MH077607 (C.M.N.), the Molecular Libraries Probe Center Network (U54MH084659 to C.W.L.), R01MH073676 (PJC) and U01MH087965 (Vanderbilt NCDDG). We also thank William K. Warren, Jr. and the William K. Warren Foundation who funded the William K. Warren, Jr. Chair in Medicine (to C.W.L.). We also thank key CROs that performed key higher species PK (Frontage), pharmaceutical science/X-ray work (Crystal Pharmatech) and Pgp assays (Absorption Systems).

References

1. Chan WY, McKinize DL, Bose S, Mitchell SN, Witkins JM, Thompson RC, Christopoulos A, Birdsall NJ, Bymaster FP, Felder CC. *Proc Natl Acad Sci USA*. 2008; 105:10978–10983. [PubMed: 18678919]
2. Leach K, Loiancono RE, Felder CC, McKinize DL, Mogg A, Shaw DB, Sexton PM, Christopoulos A. *Neuropsychopharmacology*. 2010; 35:855–869. [PubMed: 19940843]
3. Brady A, Jones CK, Bridges TM, Kennedy PJ, Thompson AD, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey J, Conn PJ, Lindsley CW. *J Pharm & Exp Ther*. 2008; 327:941–953.
4. Pancani T, Foster DJ, Bichell T, Bradley E, Bridges TM, Klar R, Daniels JS, Jones CK, Bowman AB, Lindsley CW, Xiang Z, Conn PJ. *Proc Natl Acad Sci USA*. 2015; 112:14078–14083. [PubMed: 26508634]
5. Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, Patel S, Marnett LJ, Niswender CM, Jones CK, Xiang Z, Lindsley CW, Rook JM, Conn PJ. *Neuron*. 2016; 91:1224–1252.
6. Byun NE, Grannan M, Bubser M, Barry RL, Thompson A, Rosanelli J, Gowrishnakar R, Kelm ND, Damon S, Bridges TM, Melancon BJ, Tarr JC, Brogan JT, Avison MJ, Deutch AY, Wess J, Wood MR, Lindsley CW, Gore JC, Conn PJ, Jones CK. *Neuropsychopharmacology*. 2014; 39:1578–1593. [PubMed: 24442096]
7. Farrell M, Roth BL. *Neuropsychopharmacology*. 2010; 35:851–852. [PubMed: 20145632]
8. Jones CK, Byun N, Bubser M. *Neuropsychopharmacology*. 2012; 37:16–42. [PubMed: 21956443]
9. Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, Weaver D, Niswender CM, Conn PJ. *Nat Chem Bio*. 2008; 4:42–50. [PubMed: 18059262]
10. Le U, Melancon BJ, Bridges TM, Utley TJ, Lamsal A, Vinson PN, Sheffler DJ, Jones CK, Morrison R, Wood MR, Daniels JS, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR. *Bioorg Med Chem Lett*. 2013; 23:346–350. [PubMed: 23177787]
11. Kennedy JP, Bridges TM, Gentry PR, Brogan JT, Brady AE, Shirey JK, Jones CK, Conn PJ, Lindsley CW. *ChemMedChem*. 2009; 4:1600–1607. [PubMed: 19705385]
12. Salovich JM, Sheffler DJ, Vinson PN, Lamsal A, Utley TJ, Blobaum AL, Bridges TM, Le U, Jones CK, Wood MR, Daniels JS, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR. *Bioorg Med Chem Lett*. 2012; 22:5084–5088. [PubMed: 22738637]
11. Bubser M, Bridges TM, Thorbeck DD, Gould RW, Grannan M, Noetzel MJ, Niswender CM, Daniels JS, Melancon BJ, Tarr JC, Wess J, Duggan ME, Brandon NJ, Dunlop J, Wood MW, Wood MR, Lindsley CW, Conn PJ, Jones CK. *ACS Chem Neurosci*. 2014; 5:920–942. [PubMed: 25137629]
12. Smith E, Chase P, Niswender CM, Conn PJ, Lindsley CW, Madoux F, Acosta M, Scampavia L, Spicer T, Hodder P. *J Biomol Screening*. 2015; 20:858–868.
13. Wood MR, Noetzel MJ, Tarr JC, Rodriguez AL, Lamsal A, Chang S, Foster JJ, Smith E, Hodder PS, Engers DW, Niswender CM, Brandon NJ, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW. *Bioorg Med Chem Lett*. 2016; 26:4282–4286. [PubMed: 27476142]
14. Wood MR, Noetzel MJ, Engers JL, Bollinger KA, Melancon BJ, Tarr JC, Han C, West M, Gregro AR, Lamsal A, Chang S, Ajmera S, Smith E, Chase P, Hodder PS, Bubser M, Jones CK, Hopkins CR, Emmitte KA, Niswender CM, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW. *Bioorg Med Chem Lett*. 2016; 26:3029–3033. [PubMed: 27185330]
15. Wood MR, Noetzel MJ, Poslunsey MS, Melancon BJ, Tarr JC, Lamsal A, Chang S, Luscombe VB, Weiner RL, Cho HP, Bubser M, Jones CK, Niswender CM, Wood MW, Brandon NJ, Engers DW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW. *Bioorg Med Chem Lett*. 2017; 27:171–175. [PubMed: 27939174]
16. Wood MR, Noetzel MJ, Melancon BJ, Nance KD, Poslunsey MS, Hurtado MA, Luscombe VB, Weiner RL, Rodriguez AL, Lamsal A, Chang S, Bubser M, Blobaum AL, Engers DW, Niswender CM, Jones CK, Brandon NJ, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW. *ACS Med Chem Lett*. 2017; 8:233–238. [PubMed: 28197318]
17. Experimental for the synthesis of **8p** (VU0476406), 5-amino-*N*-(4-(2-fluoropyridine-3-yl)benzyl)-3,4-dimethylthieno[2,3-*c*] pyridazine-6-carboxamide. To a 5 mL microwave vial

equipped with a stir bar was added 5-amino-*N*-(4-bromobenzyl)-3-dimethylthieno[2,3-*c*]pyridazine-6-carboxamide (50 mg, 0.13 mmol), (2-fluoropyridin-3-yl)boronic acid (36 mg, 0.26 mmol), 10 mol% Pd(dppf)Cl₂·CH₂Cl₂ (10.3 mg, 0.013 mmol). The microwave vial was sealed, evacuated and back-filled three times with argon. Then, an aqueous solution of potassium phosphate (380 μL, 1 M K₃PO₄ in H₂O, 0.38 mmol) was added, followed by THF (1.3 mL). The biphasic mixture was heated at 160 °C for 20 min, and after cooling, the suspension was diluted with DCM and filtered through celite. Silica gel chromatography afforded **8p** as an orange solid (40 mg, 80%). LCMS: R_T = 0.623 min, >99% @254 nm, >99% @215 nm; m/z (M+1) = 408. ¹H NMR (400 MHz, CDCl₃, d (ppm)): 8.7 (t, J=4.0 Hz, 1H), 8.2 (d, J=4.0 Hz, 1H), 8.1–8.0 (m, 1H), 7.6 (d, J=8.0 Hz, 2H), 7.5–7.4 (m, 3H), 6.9 (bs, 2H), 4.5 (d, J=4.0 Hz, 2H), 2.71 (s, 3H), 2.70 (s, 3H). HRMS calc'd for C₂₁H₁₉FN₅OS (M+H), 408.1294; found 408.1298.

18. Whole and regional brain distribution of total and calculated unbound VU0476406 was determined in NHP (cynomolgus monkey, *n* = 1) via a PET study employing a single IV administration of [¹⁸F]-VU0476406 (145 MBq) and an approximate 2 hour data acquisition time post-administration; manuscript in preparation.
19. Prediction of human CL_P was performed using two approaches: 1) the mean hepatic extraction ratio (ER_{hep}) observed in rat, dog, and NHP (0.17) applied to human Q_{hep}; 2) *in vitro* to *in vivo* extrapolation of CL_{int} (human hepatic microsomes) using the well-stirred model of organ clearance with inclusion of human *f*_{uplasma} and predicted *f*_{umic} terms. Predicted human *t*_{1/2} was obtained from predicted CL_P and a predicted V_{ss} (1.9 L/kg) scaled allometrically from the observed rat and dog V_{ss} with correction for species differences in *f*_{uplasma}.
20. Shen W, Plotkin JL, Francardo V, Ko WKD, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengrad P, Bezard E, Cenci MA, Surmeier DJ. Neuron. 2015; 88:762–773. [PubMed: 26590347]

Figure 1.
Structures of representative M₄ PAMs 1–4, exemplifying an optimized rodent *in vivo* tool M₄ PAM, VU0467154 (3) and the clinical candidate VU0467485/AZ13713945 (4).

Figure 2.

M₄ PAM concentration response curves (CRCs) for **8p** (VU0476406) at human (hM₄ EC₅₀ = 91.0 nM, pEC₅₀ = 7.04±0.11, 74±3% ACh Max), rat (rM₄ EC₅₀ = 13.5 nM, pEC₅₀ = 7.93±0.17, 72±4% ACh Max), cyno (cM₄ EC₅₀ = 87.3 nM, pEC₅₀ = 7.06±0.25, 64±2% ACh Max) and dog (dM₄ EC₅₀ = 111 nM, pEC₅₀ = 6.95±0.12, 49±4% ACh Max).

Figure 3.

In vitro biotransformation of **8p** (VU0476406) in cryopreserved hepatocytes from multiple species (rat, dog, cynomolgus monkey, and human).

Figure 4.

X-ray crystal structure (CCDC 1538487) of **8p**. A) Clear intra- and intermolecular hydrogen bonds are present (H-bond between pyridine and amide is linear, H-bond network forms a helix). B) All aryl/heteroaryl rings are oriented to allow π -stacking on both faces. Unit cell dimensions: $22.3 \times 16.8 \times 5.04$ Å. Combined, this crystalline lattice explains the compound's poor aqueous solubility.

Scheme 1. Synthesis of M₄ PAM analogs **8.^a**

^aReagents and conditions: (a) Methyl thioglycolate, MeOH, 1M aq. NaOH, 150 °C, microwave, 30 min, 78%; (b) bromobenzyl amine, HATU, DMF, DIPEA, 2 h, 45–92%; (c) 5 mol% Pd(dppf)Cl₂·CH₂Cl₂, Bu₃SnAr(Het), THF, 65–80% or 5 mol% Pd(dppf)Cl₂·CH₂Cl₂, (HO)₂BAr(Het), K₃PO₄, THF/H₂O, 100 °C, 58–90%.

Table 1Structures and activities for human M₄ PAM analogs **7** and **8**.

<p style="text-align: center;">8</p>			
Cpd	R	hM ₄ EC ₅₀ (nM) ^a [% ACh Max ± SEM]	hM ₄ pEC ₅₀ (±SEM)
7a		>10,000 [31±2]	>5
7b		185 [84±2]	6.77±0.13
7c		187 [82±2]	6.74±0.07
8a		>10,000 [30±1]	>5
8b		1,650 [41±3]	5.80±0.12
8c		319 [49±6]	6.53±0.12
8d		232 [75±5]	6.67±0.12
8e		103 [63±4]	7.20±0.31
8f		36 [83±8]	7.57±0.19

<p style="text-align: center;">8</p>			
Cpd	R	hM ₄ EC ₅₀ (nM) ^d [% ACh Max ± SEM]	hM ₄ pEC ₅₀ (±SEM)
8g		56 [96±5]	7.26±0.06
8h		159 [63±6]	7.00±0.29
8i		84 [91±9]	7.08±0.04
8j		230 [65±11]	6.67±0.11
8k		58 [92±10]	7.31±0.16
8l		1,716 [86±5]	5.81±0.14
8m		64 [79±2]	7.20±0.06
8n		144 [78±14]	6.84±0.04
8o		994 [68±1]	6.11±0.22
8p		91 [74±3]	7.04±0.11

^a Calcium mobilization assays with hM4/Gq15-CHO cells performed in the presence of an EC₂₀ fixed concentration of acetylcholine; values represent means from three ($n=3$) independent experiments performed in triplicate.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2*In vitro* and *in vivo* DMPK properties of **8f**, **8k**, **8m** and **8p**.

Property	8f	8k	8m	8p
MW	398.4	407.4	407.4	407.4
cLogP	2.66	2.92	2.92	2.92
TPSA	93.4	93.8	93.8	93.8
<i>In vitro</i> PK parameters				
CL _{INT} (mL/min/kg), rat	415	57.1	81.6	134.0
CL _{HEP} (mL/min/kg), rat	59.9	31.5	37.7	46.0
CL _{INT} (mL/min/kg), human	20.1	19.6	20.2	19.2
CL _{HEP} (mL/min/kg), human	15.2	17.8	17.1	14.8
Rat fu _{plasma}	0.037	0.002	0.004	0.002
Human fu _{plasma}	0.013	0.029	0.023	0.011
Rat fu _{brain}	0.042	ND	ND	0.020
Cytochrome P ₄₅₀ (IC ₅₀ , μ M)				
1A2	9.7	2.5	0.79	11
2C9	2.3	25	26	>30
2D6	1.3	>30	>30	19
3A4	0.34	24	25	>30
IV Pharmacokinetics (SD Rat; 0.1–1.0 mg/kg)				
CL _p (mL/min/kg)	9.0	3.6	1.7	1.6
Elimination t _{1/2} (hr)	1.5	1.7	0.48	2.7
V _{ss} (L/kg)	1.1	0.50	0.60	0.34
Brain Distribution (0.25 hr) (SD Rat; 0.1–0.2 mg/kg IV)				
K _{p, brain:plasma}	0.94	0.21	0.13	0.11
K _{p,uu, brain:plasm}	1.1	ND	ND	1.2
MDCK-MDR1 (Pgp) ER	1.1	ND	ND	1.7

ND = not determined.